Acer Therapeutics — Investor Presentation (June 2018)
28 slides from Acer Therapeutics's investor presentation, Jun 29, 2018
Slide 1: Developing Therapeutics for the Treatment of Serious Rare Diseases
Developing Therapeutics for the Treatment of Serious Rare Diseases with Significant Unmet Medical Needs July 2018 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Acer Corporate Overview
Acer is a pharmaceutical company that acquires, develops and commercializes therapies for serious rare and ultra-rare diseases with significant unmet medical needs. Headquartered: Newton, MA Headcount: 15 Founded: December 2013 Public: September 2017 Cash: $12.4M (3/31/18) Expected to have sufficien
Slide 4: Senior Management
Senior Management Chris Schelling CEO & Founder 19 years; strategic commercial development & orphan Will Andrews, MD Chief Medical Officer 18 years; clinical development, medical affairs & orphan M.D. Yale University School of Medicine Harry Palmin Chief Financial Officer 25 years; corporate & finan
Slide 5: Investment Highlights
Investment Highlights Lead candidate (EDSIVO™) is a new chemical entity (NCE) for treatment of vascular Ehlers-Danlos syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of potential launch ACER-001 for treatment of Urea Cycle Disorders (UCD)
Slide 6: Clinical Pipeline
Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 3 NDA Market EDSIVOTM (celiprolol) vEDS (COL3A1+) Improves hemodynamic stability; decreases vascular resistance ACER-001 (reformulated sodium phenylbutyrate) UCD Comparable to Buphenyl; taste-masked MSUD Inhibition of BCKD
Slide 7: EDSIVO Overview
Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and/or ruptures Median survival is 51 years of age Identified in over 2,000 COL3A1+ vEDS patients in the U.S. Vascular
Slide 8: Vascular Ehlers-Danlos syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Gastrointestinal Uterine Autosomal dominant (50%); spontaneous mutations (50%) Diagnosed by clinical symptom
Slide 9: EDSIVO Unique Mechanism of Action
Cardiology in Review 2017;25: 247–253 EDSIVO™ Unique Mechanism of Action EDSIVO™ has a unique pharmacological profile: Selective β1 and ⍺2 adrenergic receptor antagonist β2 and β3 adrenergic receptor agonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Void of blood
Slide 10: Pivotal Trial Design
Multicenter, prospective, randomized, open trial with blinded endpoint assessment Design: 9 sites: eight in France, one in Belgium Location: Inclusion criteria adapted Villefranche diagnostic criteria: 1 major criterion and 2 minor criteria, or 4 minor criteria needed for enrollment Eligibility: 53
Slide 11: EDSIVO Statistically Significant Efficacy
Results & Analysis: Trial stopped early for treatment benefit (mean follow-up 47 months) The primary endpoint (arterial dissection or rupture) affected 5 (20%) celiprolol patients and 14 (50%) controls (hazard ratio [HR] 0.36; p=0.04) Primary and secondary endpoints (intestinal or uterine rupture) a
Slide 12: Paris vEDS Patient Registry
Paris vEDS Patient Registry Assistance Publique – Hôpitaux de Paris (AP-HP) Registry PIs: Michael Frank, Xavier Jeunemaitre 144 patients enrolled in registry 100% of patients in registry have COL3A1 gene mutation >80% of patients treated with celiprolol Study Period: Jan. 2000 to Dec. ‘14 (for initi
Slide 13: U.S. vEDS Natural History
U.S. vEDS Natural History 13 Pepin Genet Med. 2014 Dec;16(12):881-8. Median Survival: 51 years (46 y.o. males; 54 y.o. females) 1,231 patients (>90% COL3A1+; 630 index; 601 relatives)
Slide 14: EDSIVO Regulatory Plan
EDSIVO™ Data Package Pivotal Clinical Trial n = 53 patients (62% COL3A1+) Statistically-significant improvement in 1º endpoint EFS (p=0.04) Paris Registry: n = 144 patients (100% COL3A1+) >80% patients on celiprolol Compare with U.S. Natural History study (Pepin 2014) Presented to FDA at Type C meet
Slide 15: vEDS Market Sizing
vEDS Market Sizing* vEDS patient population for basis of market sizing = 4,169 patients 2 instances of the EDS Dx Code 756.83 separated by ≥ 2 months Includes at least one other Dx or CPT code relevant to vEDS -AND- Excludes hypermobility syndrome * Study conducted on 06/2017; based on sampling of p
Slide 16: Accelerate Diagnosis
Accelerate Diagnosis https://www.genetests.org/genes/?gene=COL3A1 * Based on sampling of phenotype, rather than genotype Facial Recognition Program Patients with vEDS have relatively similar / identifiable facial features Want a quick, cost-effective test to potentially help screen for vEDS patients
Slide 17: vEDS Patient and Payer Demographics
17 vEDS Patient and Payer Demographics
Slide 18: EDSIVO Proposed Commercial Strategy
EDSIVO™ Proposed Commercial Strategy EDSIVO™ Proposed Launch Plan* Identify vascular medicine specialists / cardiologists who: Can manage patients and their families Are familiar with orphan therapies Refer to CV surgeons Work closely with a team of specialists Will focus initially on cardiology/vas
Slide 19: EDSIVO HEOR
19 EDSIVO™ HEOR Precision Health Economics is developing a health economic (cost-consequence) model demonstrating the economic and clinical value of vEDS Centers of Excellence, and the potential impact of EDSIVO™ on patient outcomes These models will help quantify and communicate cost offsets associ
Slide 20: EDSIVO Market Opportunity
If approved, EDSIVO™ will be the only FDA-approved therapy to treat vEDS patients 2,000 to 5,000 vEDS patients in the U.S. Orphan pricing well supported by initial payer research, with additional validation from HEOR models Provide a robust patient assistance program (PAP) to help offset costs (so t
Slide 21: ACER-001 Overview
A group of metabolic genetic diseases that lead to toxic build-up of NH4+ Currently treated with Ravicti, Buphenyl, Ammonul, and a highly-restricted diet >2,000 patients with UCD in the U.S.; ~600 patients treated with sodium / glycerol phenylbutyrate Urea Cycle Disorders (UCD) A metabolic genetic d
Slide 22: Urea Cycle Disorders (UCD)
Urea cycle disorders are a group of genetic disorders caused by mutations that result in a deficiency of one of the six enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the blood stream The estimated incidence of urea cycle disorders is 1 in 8,500 births Treatment o
Slide 23: Sodium phenylbutyrate lowers branched-chain amino acids
In addition to lowering levels of ammonia in patients with urea cycle disorders (UCD), sodium phenylbutyrate (NaPB) also significantly reduces branched-chain amino acids (BCAAs)1 NaPB’s ability to lower leucine and other BCAAs could provide clinically-meaningful benefit in another genetic disease: M
Slide 24: Maple Syrup Urine Disease (MSUD)
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 25: ACER-001 Taste-Masked, Immediate Release
ACER-001 Taste-Masked, Immediate Release Mouth → Stomach Excellent protection for several minutes at mouth pH followed by rapid release at stomach pH Phenylbutyrate Formulations ACER-001 RAVICTI BUPHENYL Efficacy/Safety in UCD ✓ ✓ ✓ Efficacy/Safety in MSUD ✓ ✘ ✓ Palatability / Compliance ✓ ✓ ✘ Reaso
Slide 26: ACER-001 Market Opportunity
Cannibalize existing sodium phenylbutyrate market share in UCD Taste-masked, immediate-release formulation Competitively priced Life cycle expansion opportunity in MSUD Barriers to entry: Filed formulation patent application (January 2016) Issued patent (US/EP) “Methods of modulation of branched cha
Slide 27: Acer Financial Overview
Acer Financial Overview Cash: $12.4M (3/31/18) Expected to have sufficient capital through the end of 2018 Capitalization at March 2018 7.5M shares of common stock outstanding 8M shares of common stock fully diluted $40.6M invested to date through December 2017 TVM Capital has been the lead investor
Slide 28: Acer Summary
Acer Summary Lead candidate (EDSIVO™) is a new chemical entity (NCE) for treatment of vascular Ehlers-Danlos syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of potential launch ACER-001 for treatment of Urea Cycle Disorders (UCD) and Maple
Acer Therapeutics — Investor Presentation (June 2018) on 6ix